Drug intelligence / Profile preview

HS-10502 + bevacizumab

Development stage: Unknown
Lead developer: Hansoh Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

HS-10502 + bevacizumab is a **combination drug** under investigation for treatment of advanced solid tumors. HS-10502 is an oral, selective inhibitor of **PARP1** (poly(ADP-ribose) polymerase 1), targeting DNA repair mechanisms crucial for certain cancer cell survival. Bevacizumab is a **recombinant humanized monoclonal antibody** that inhibits **vascular endothelial growth factor A (VEGF-A)**, thereby blocking angiogenesis and reducing tumor blood supply. The combination is being studied in recurrent ovarian cancer, HER2-negative advanced breast cancer, triple-negative breast cancer (TNBC), advanced prostate cancer, advanced gastric cancer, and HRD-positive advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Other names: HS-10502 + bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on HS-10502 + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10502 + bevacizumab.

Explore the full profile